杭州城市河道生态治理实践及成效

评估杭州市城市河道生态治理成效,为更好地指导城市河道生态修复工作提供借鉴.后横港、沿山河、新塘河和南大河位于杭州市中心城区,水质都处于劣V类,蓝藻水华和黑臭暴发频繁,从2014年开始,分别开展了一系列生态修复工程.测定氨氮、总磷、高锰酸盐指数、溶解氧指标判断水质改善情况,分析浮游植物、浮游动物、底栖动物判断水体生态修复程度.氨氮后横港下降超过80%,沿山河和南大河下降60%左右;总磷后横港下降接近70%,其他河道下降23%~55%;后横港、沿山河、新塘河高锰酸盐指数进一步降低,部分河道高锰酸盐指数能达到II类水水平;溶解氧浓度都明显上升,均能达到III类以上水平.南大河的浮游植物密度达到了水华暴发的水平;各条河道的原生动物和轮虫类密度都较高,但Shannon多样性指数普遍在1~2;枝角类和桡足类密度偏低;底栖动物Shannon指数均低于1,指示河道处于严重污染状态.杭州市城市河道生态治理工作的中心是:沉水植物恢复及以沉水植物恢复为基础、包含浮游动物和底栖动物等在内全水域生物多样性恢复的生态系统恢复

伊犁河谷红地球葡萄标准化栽培技术研究及产业化建设

课题根据伊犁河谷红地球葡产区的气候条件，确定了红地球葡萄的定植方式采用小棚架栽植效果好，修剪方式采用“独龙干”和“双龙干”较为适宜，确定了疏花疏果时间及技术，提高了红地球葡萄一级果率，其中鲜食葡萄二次套袋法技术，既可以有效的防止果穗日灼现象的发生，同时又可控制果实颜色，防止果穗的污染；确定了红地球葡萄防止日灼的主要方法是：果穗套袋、增加遮荫面积和采用棚架栽培，抬高结果部位等，采用滴灌方式进行灌溉，既达到了经济用水降低生产成本的目的，规范了红地球葡萄无公害生产整个环节的技术规程，红地球葡萄的七个标准化栽培技术规程在生产过程中的贯彻实施；初步形成了“果农＋基地＋协会＋经销商”产业化模式。 成果类别： 应用技

草炭绿化荒漠

1993-1996年与日本草炭研究会开始“草炭绿化荒漠”的研究工作,1997-2000年开始执行中日政府间JICA合作研究,1998年9月-2001年9月开始中国科学院重大国际合作特别支持项目。该项目以中国科学院阜康荒漠生态试验站为基地,利用草炭改良荒漠,寻求绿化荒漠的新方法、新技术,改善干旱区环境为目的。研究包括草炭的基本性质、土壤-植物系统与水份关系、草炭改土效果、草炭制剂的研究制、草炭利用新技术、草炭的土壤中分解速率和利用年限、草炭绿化荒漠机理等。研制的“草炭土壤调理剂”获发明专利,该制剂可为作物提供全方位的水份和养份供应,为有机肥工业化提供了良好前景;研究方法上采用了盆栽、小区和同位素..

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials